It has also accused India of not allowing foreign direct investment (FDI) in crucial sectors.
In the report, 2013 National Trade Estimate Report on Foreign Trade Barriers, issued by the office of the United States Trade Representative (USTR), the US accused India of lacking “effective protection against unfair commercial use of undisclosed tests and other data generated to obtain marketing approval for pharmaceutical and agrochemical products.”
Also Read
“The recent decision of the Supreme Court rejecting the patent plea in the Novartis case has reiterated that India’s interpretation of Section 3(d) of the Indian Patent Act has balanced its public health interests with that of innovation. Further, the granting of a compulsory licence to Natco in the case of the Nexavar drug is an indication that India believes its actions are in consonance with the flexibility the TRIPS agreement offers,” a senior commerce ministry official said.
The USTR also said India imposed several barriers in major services industries such as insurance, banking, audiovisual services, accounting, legal services, telecommunications, distribution services, postal and express delivery services. India, which accounted for 12 of the 406 pages in the report, was also criticised for not allowing foreign participation in some of these sectors.
“This is based on India’s national interest. On the contrary, India views with serious concern the steep hike in visa fees under the public law of the US, which has implications for US obligations under the WTO. India believes further liberalisation of the services sector would be possible on a multilateral basis, rather than on plurilateral efforts,” the commerce ministry official said.
On the US accusing India of having a “stringent and non-transparent” FDI policy, the official said this was tantamount to “interfering in the sovereign policy space of India. The report reflects a biased picture on India’s policy requirements in order to protect US export interests and refutes it unequivocally”.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)